Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29472356 | 1.00 | P2RX7 (0.35) | P2RX7TNFRIPK1HTR2AHTR2C | |
| SCHEMBL489658 | 0.80 | CES2 (0.37) | P2RX7RIPK1 | |
| SCHEMBL2177099 | 0.77 | P2RX7 (0.38) | P2RX7TNFRIPK1 | |
| SCHEMBL29799944 | 0.77 | PNMT (0.46) | P2RX7HTR2AHTR2CPDCD1LG2CD274 | |
| SCHEMBL1765164 | 0.77 | PNMT (0.46) | P2RX7HTR2AHTR2CPDCD1LG2CD274 | |
| SCHEMBL12524902 | 0.77 | P2RX7 (0.40) | P2RX7RIPK1 | |
| SCHEMBL27709212 | 0.77 | P2RX7 (0.38) | P2RX7TNFRIPK1 | |
| SCHEMBL17694380 | 0.77 | GABRA1 (0.36) | P2RX7TNFHTR2AHTR2C | |
| SCHEMBL30031464 | 0.76 | MEP1B (0.34) | P2RX7HTR2AHTR2C | |
| SCHEMBL26971199 | 0.76 | MEP1B (0.34) | P2RX7HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-12208110-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-11963967-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4228685-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| CN-116322759-A | Phospholipid compounds and uses thereof | 吉利德科学公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2021-05-04 | — | — | US | disclosed |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2020-09-10 | — | — | US | disclosed |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2020-09-10 | — | — | US | disclosed |
| EP-3377491-B1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2019-11-13 | — | — | EP | disclosed |
| EP-3377491-B1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2019-11-13 | — | — | EP | disclosed |
| EP-3377491-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-7973047-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
| US-7745484-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | P2RX7 832/4885TNF 3438/4885RIPK1 1191/4885 |
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | P2RX7 2345/4885TNF 4135/4885RIPK1 1344/4885 |
| US-12208110-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS1, SGMS2 | P2RX7 572/4885TNF 3809/4885RIPK1 1394/4885 |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | P2RX7 790/4885TNF 4350/4885RIPK1 2633/4885 |
| US-11963967-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | P2RX7 790/4885TNF 4350/4885RIPK1 2633/4885 |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | P2RX7 1629/4885TNF 4363/4885RIPK1 848/4885 |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | P2RX7 1399/4885TNF 611/4885RIPK1 4577/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | P2RX7 1399/4885TNF 611/4885RIPK1 4577/4885 |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | P2RX7 2345/4885TNF 4135/4885RIPK1 1344/4885 |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | P2RX7 832/4885TNF 3438/4885RIPK1 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.